Yes, DSIP (Delta Sleep-Inducing Peptide) has been studied for its potential in managing withdrawal symptoms, particularly in cases of alcohol and opiate withdrawal
After at least 4 weeks with a dose of 0.5mg once weekly, the dose can be increased to 1mg
Long-term effects, potential drug interactions, and effects in specific populations including pregnant women, children, and those with certain medical conditions have not been studied
Cognitive and Neurological Support Though still emerging, GHK-Cu shows promise for: Reducing oxidative stress in neurons Supporting cognitive resilience Enhancing neurogenesis It is being explored as an adjunct therapy in TBI , neurodegeneration , and stroke recovery
Nature Communications 2024;15(1)